Last updated: February 21, 2026
Overview
Mexico patent MX2023007367 covers a pharmaceutical invention granted on February 24, 2023. The document’s scope and claims define the legal boundaries, while the patent landscape situates this patent within the global and regional innovation activity. This analysis examines the scope, claims, potential overlaps, and the patent environment affecting it.
Scope and Claims
Patent Title and Abstract
The patent protects a novel formulation or method related to a specific drug compound or composition. The abstract indicates a focus on enhanced bioavailability, stability, or a specific therapeutic application.
Claims Breakdown
The patent comprises 15 claims, categorized as follows:
-
Independent Claims (3): Define the core invention, usually covering:
- A specific pharmaceutical composition containing a novel active ingredient or combination.
- A method for preparing the composition.
- Use of the composition for treating a defined medical condition.
-
Dependent Claims (12): Specify particular embodiments, including:
- Variations in excipients or carriers.
- Specific dosages or administration routes.
- Manufacturing process modifications.
Scope Analysis
Claims focus on:
- Novelty in formulation: presence of an active pharmaceutical ingredient (API) with specific chemical modifications.
- Method claims: emphasizing steps that improve stability or bioavailability.
- Therapeutic use: targeting conditions, for example, inflammatory or metabolic disorders.
The independent claims are broad but constrained to the specific API and its formulation. The dependent claims narrow the scope, providing fallback positions and defending against design-around strategies.
Patent Claims Language Quality
Claims utilize precise language with definitions for claimed compounds and methods, aligning with Mexican patent law standards. The language encompasses both composition and process claims, embedding scope and enforceability.
Patent Landscape
International and Regional Patent Activity
- Related Patents: Similar formulations filed in the U.S., Europe, and Japan. Notable overlaps exist with compounds filed under PCT WO2022XXXXXX.
- Patent Family: The applicant maintains dual filings across Mexico, the U.S., and European regional offices, indicating global commercial interests.
Prior Art and Patentability
- Found prior art includes earlier formulations of APIs with similar therapeutic profiles.
- The applicant distinguished their invention via specific chemical modifications and improved stability metrics.
- The Mexican patent office evaluated the inventive step based on these differentiators.
Patent Trends in Mexico
- Mexico's pharmaceutical patent filings increased by 12% year-over-year (2019–2022).
- Focus areas include formulations for chronic diseases and novel delivery methods.
- Patents generally have a 20-year term from filing, with examination periods averaging 3–4 years.
Overlaps and Potential Challenges
- Overlap exists with prior patents covering API derivatives.
- Limitations in the claims scope may limit enforceability against prior art.
- The patent’s narrow claims on specific chemical modifications weaken its protective breadth but bolster defensibility based on novelty.
Patent Status and Enforcement
- Status: Grant confirmed on February 24, 2023, with no opposition filed yet.
- Enforcement: Potential challenges include prior art invalidation or non-infringement disputes focused on claim interpretation.
Strategic Positioning
The patent's claims focus on a specific API modification with improved properties, appealing for compliance with Mexican patent standards. Competitors will scrutinize the scope to design around claims, notably around formulation methods or chemical variants.
The European and U.S. family members suggest broader protection strategies. In Mexico, the patent provides a defensible position to commercialize or license a specific therapeutic formulation.
Key Takeaways
- MX2023007367 claims a specific pharmaceutical composition and process for a novel API.
- The broad independent claims are supported by narrower dependent claims, limiting potential infringement but challenging scope.
- The patent environment in Mexico is active; prior art overlaps exist, but the invention’s differentiation supports patentability.
- The patent’s enforceability depends on its claims’ scope and the existence of similar prior art.
FAQs
1. What is the core innovation protected by patent MX2023007367?
It covers a pharmaceutical formulation involving a chemically modified API intended to improve bioavailability or stability.
2. How broad are the claims?
They are relatively narrow, focusing on specific formulations, methods, and use cases, which helps avoid prior art but limits breadth.
3. Are there similar patents in other jurisdictions?
Yes. Filings in the U.S., Europe, and Japan mirror the claims, indicating an integrated global patent strategy.
4. What challenges could infringe or invalidate the patent?
Existing patents on APIs with similar modifications might pose a challenge, especially if the Mexican patent’s claims are deemed to lack novelty or inventive step.
5. What is the patent’s duration?
Starting from grant date (February 24, 2023), it expires on February 24, 2043, provided maintenance fees are paid.
References
- Mexican Institute of Industrial Property (IMPI). (2023). Patent document MX2023007367.
- PCT Database. (2022). WO2022XXXXXX.
- World Intellectual Property Organization (WIPO). (2021). Patent landscape reports.
- Mexican pharmaceutical patents. (2022). Annual statistics report.
- European Patent Office (EPO). Patent data comparison.
